Oksuz, S.; Kinikoglu, O.; Ozkerim, U.; Altintas, Y.E.; Isik, D.; Surmeli, H.; Odabas, H.; Ay, S.; Basoglu, T.; Turan, N.
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine. Medicina 2025, 61, 819.
https://doi.org/10.3390/medicina61050819
AMA Style
Oksuz S, Kinikoglu O, Ozkerim U, Altintas YE, Isik D, Surmeli H, Odabas H, Ay S, Basoglu T, Turan N.
Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine. Medicina. 2025; 61(5):819.
https://doi.org/10.3390/medicina61050819
Chicago/Turabian Style
Oksuz, Sila, Oguzcan Kinikoglu, Ugur Ozkerim, Yunus Emre Altintas, Deniz Isik, Heves Surmeli, Hatice Odabas, Seval Ay, Tugba Basoglu, and Nedim Turan.
2025. "Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine" Medicina 61, no. 5: 819.
https://doi.org/10.3390/medicina61050819
APA Style
Oksuz, S., Kinikoglu, O., Ozkerim, U., Altintas, Y. E., Isik, D., Surmeli, H., Odabas, H., Ay, S., Basoglu, T., & Turan, N.
(2025). Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine. Medicina, 61(5), 819.
https://doi.org/10.3390/medicina61050819
